Arecor, CPI and FUJIFILM Diosynth Biotechnologies collaborate
Arecor, CPI and FUJIFILM Diosynth Biotechnologies collaborate to apply smart formulation approaches in the manufacturing of biopharmaceuticals under a grant awarded by Innovate UK.
Arecor CEO announces resignation
Thomas Saylor is retiring as CEO of Arecor, the position in which he has effectively served for the past eight years.
FluGen-Arecor successfully completes project to develop stable liquid universal flu vaccine
FluGen-Arecor partnership successfully completes Innovate UK SMART Grant-funded project to develop stable liquid formulations of promising Universal Flu Vaccine REDEE FLU™.
Arecor awarded TSB grant to support expanded protein stability platform
Arecor Limited has been awarded a prestigious Technology Strategy Board (TSB) grant to apply its proprietary technology for developing stable formulations of protein drugs.
GALVmed-Arecor collaborate to pursue new vaccine formulations for developing world livestock
New vaccine formulations to combat two major diseases of livestock in the developing world are to be pursued through a partnership between livestock medicines charity, GALVmed and the biotechnology company, Arecor Limited.
CPI collaborate with Arecor to enhance compatibility of biologic medicines with containers
The Centre for Process Innovation (CPI) is working with Arecor to enhance the compatibility of biologic medicines with containers, and thereby improve stability and shelf life throughout transportation and storage.
Arecor presents data for Arestat™ formulation technology
At the World Vaccine Congress in Washington DC next week, Arecor will present data showing how its Arestat™ formulation technology significantly improves temperature stability for major vaccine types.
Arecor launches new platform tool for viscosity reduction in high concentration biologics
Arecor, the Cambridge biotechnology company specialising in the stabilisation of biopharmaceuticals, announced today a key addition to its Arestat(TM) platform, through the creation of a novel and proprietary formulation design tool to reduce the viscosity of liquid biologic formulations, enabling higher concentration doses in easy-to-administer prefilled syringe formats.
FluGen-Arecor partnership enhances promise of universal flu vaccine
Arecor Ltd of Cambridge received the “green light” and funding to pursue a research project applying Arecor’s innovative Arestat™ formulation technology to a promising flu vaccine, REDEE FLU™, developed by FluGen, Inc., of Madison, WI.
Arecor granted key US patent for metalloprotein stabilisation
Arecor, the Cambridge biotechnology company specialising in the stabilisation of biopharmaceuticals, announced today the granting of US Patent No. 8486388, which protects a pioneering formulation design tool within its Arestat(TM) platform, to enable stable ready-to-use liquid formulations of metalloproteins such as blood coagulation medicines.
Arecor patents ground breaking heat stable adenovirus vaccine technology
Arecor announces today a significant leap forward to enabling liquid-stable versions of live-virus containing products, used widely in vaccines and gene therapy products. Arecor has patented technology that enables liquid storage of adenovirus and removes a major limitation to more widespread use.
Science Minister David Willetts visits Arecor
Science Minister David Willetts this week visited Arecor to learn more about its pioneering projects after being awarded £785,000 under the government-backed Biomedical Catalyst to accelerate the development of high concentration antibodies. This will enable more convenient administration of future therapeutic medicines which will reduce healthcare costs and improve the patient experience.
Arecor awarded Biomedical Catalyst funding towards £1.3 million project
Cambridge biotech company Arecor has been awarded £785,000 from the government-backed Biomedical Catalyst Fund to accelerate the development of high concentration antibodies to allow more convenient administration of its future therapeutic medicines and reduce healthcare costs. The award will go towards a £1.3 million project to drive forward their innovative research.